Guardant DNA blood test finds 83% of colorectal cancers in trial, shares fall 35% | Reuters

Retrieved on: 2022-12-16 12:36:25

Tags for this article:

Click the tags to see associated articles and topics

Guardant DNA blood test finds 83% of colorectal cancers in trial, shares fall 35% | Reuters. View article details on hiswai:

Excerpt

O) and Illumina's Grail unit (ILMN.O), aiming to eventually secure FDA approval for DNA blood tests that can detect early-stage cancer.

Article found on: www.reuters.com